Gene Biotherapeutics Inc (CRXM) Return on Investment ROI from the fourth quarter of 2020 to fourth quarter of 2019 and for the year 2020, average high and low, overall ranking from Dec 31 2020 to Dec 31 2019 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Gene Biotherapeutics Inc   (CRXM)


Gene Biotherapeutics Inc's ROI from its fourth quarter of 2020 to the fourth quarter of 2019 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Gene Biotherapeutics Inc's ROI in the fourth quarter of 2020?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Gene Biotherapeutics Inc 's return on investment (ROI) in its fourth quarter of 2020

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2020)
IV. Quarter		 (Sep 30 2020)
III. Quarter		 (Jun 30 2020)
II. Quarter		 (Mar 31 2020)
I. Quarter		 (Dec 31 2019)
IV. Quarter
Y / Y Investment Change TTM - - - - -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions -5 -5 -4 -5 -5
Return On Investment (TTM) - - - - -
CRXM's Overall Ranking # # # # #
Seq. Investment Change TTM - - - - -
Seq. Net Income Change TTM - -16.3 % 74.99 % 10.6 % -
Net Income (TTM) in Millions -1 1 2 1 1

CRXM Company Profile >> Back to CRXM Roi Comparisons >> See Annual CRXM Return On Investment



Return On Investment CRXM's Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Investment Statistics
High Average Low
0 %
0 %
0 %
 







Financial Statements
Gene Biotherapeutics Inc's IV. Quarter Investments $ -5 Millions CRXM's Balance sheet
Gene Biotherapeutics Inc's IV. Quarter Income $ 0 Millions Quarterly CRXM's Income Statement
CRXM's Income by Division See CRXM's Income by Division


CRXM Annual Return On Investment (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015		 (Dec 31 2014)
2014
Total Investments in Millions -5 -5 -3 -4 -2
Y / Y Investment Growth - - - - -
Net Income in Millions -1 1 -3 -4 -6
Y / Y Net Income Growth - - - - -
Annual Return On Investment - - - - -


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CRXM's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CRXM's Competitors
Subscribers only: Roi for Gene Biotherapeutics Inc's Suppliers
Subscribers only: Return On Investment for CRXM's Customers

Other Ratios
CRXM's Roa CRXM's Inventory Turnover Ratio CRXM's Growth Rates CRXM's Dividend Statistics
CRXM's Profitability Ratios CRXM's Asset Turnover Ratio CRXM's Dividend Growth
CRXM's Roe CRXM's Valuation Ratios CRXM's Financial Strength Ratios CRXM's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2020, within Healthcare Sector ROI
Bio rad Laboratories Inc   37.24 %
Zomedica Corp   36.13 %
Neurocrine Biosciences Inc   35.39 %
Progyny Inc   35.03 %
Bionexus Gene Lab Corp   34.09 %
Lifevantage Corp  32.43 %
Lakeland Industries Inc   32.31 %
Halozyme Therapeutics Inc   32.13 %
Innoviva Inc   31.33 %
Vertex Pharmaceuticals Inc  31.04 %
Idexx Laboratories Inc  30.97 %
Inmode Ltd   28.79 %
Elite Pharmaceuticals Inc   28.61 %
Chemed Corporation  28.52 %
Blueprint Medicines Corporation  27.51 %
Infusystem Holdings Inc  26.94 %
Pro dex Inc   26.76 %
Regeneron Pharmaceuticals Inc   26.67 %
Mettler toledo International Inc   26.28 %
Glucotrack Inc   26.07 %
Seagen Inc   25.20 %
Ironwood Pharmaceuticals inc   23.88 %
Hologic Inc  23.80 %
Purple Biotech Ltd  23.07 %
Coherus Oncology inc   22.60 %
Corcept Therapeutics Inc  22.53 %
Genmab A  22.28 %
Zynex inc   20.44 %
Meridian Bioscience Inc   20.22 %
Eli Lilly And Company  19.78 %

Date modified: 2026-09-08T15:10:34+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.